Cambridge Healthtech Institute’s 2nd Annual
Immune Modulation, Bi-Specifics, ADCs, Synergistic Mechanisms and Unique Approaches
6-7 November 2014
Research in 2014 for this event reveals a huge increase in the interest in immunotherapy and continued interest in bi-and multi-specific products, combination approaches, and antibody drug conjugates. This conference track will present advances in all of these areas from discovery to development, and provide details on innovative modes of action, and on application and efficacy. Safety considerations for these new approaches will also be covered.
Safety Challenges and Risk Mitigation Strategies to Develop Immune Activating Biologics
Rakesh Dixit, Ph.D., Vice President, R&D, Safety Assessment, Medimmune, Inc.
ImmTACs: TCR-Based Bispecific Reagents for Targeted Cancer Therapy
Dr Annelise Vuidepot, Ph.D., Head, Protein Science, Immunocore Ltd.
Targeting Cancer with BiTE Molecules
Holger Wesche, Ph.D., Scientific Director, Oncology, Amgen, Inc.
Targeting Immune Checkpoints in Cancer: Novel Mechanistic Insights on the Role of Fc Receptors and the Tumour Microenvironment
Sergio A. Quezada, Ph.D., Professorial Research Fellow, Research Haematology, University College London Cancer Institute
Discovery and Development of Fusion Proteins and Antibodies Modulating the Immune Response in Malignancy and Enhancing Overall Effector Function
Sol Langerman, Ph.D., CSO, R&D, Amplimmune
Targeting of Solid Tumors with Bispecifics and Bispecific ADCs: Inducing Novel Biologics and Drug-Like Properties
David Poon, Director External R&D and Alliances, Zymeworks, Inc.
Preclinical Developments with a Fully-Human Bispecific Antibody Platform
Eric Smith, Ph.D., Associate Director, Bispecific Antibodies, Regeneron Pharmaceuticals, Inc.
Discovery of Novel Linkers, Payloads and Antibody-Drug Conjugates for the Treatment of Cancer
Edmund I. Graziani, Ph.D., Associate Research Fellow, Oncology Medicinal Chemistry, Pfizer, Inc.
Producing Homogeneous ADCs with Single or Combination Warheads
Aaron Sato, Ph.D., Vice President, Research, Sutro Biopharma, Inc.
Targeted Delivery of Cytotoxic Agents for Cancer Treatment
Gonçalo Bernardes, Ph.D., Royal Society, University Research Fellow, Chemistry, University of Cambridge
IgA as a Novel Antibody Isotype for the Treatment of Cancer: Potential Synergy with IgG Antibodies
Jeanette Leusen, Ph.D., Associate Professor, Translational Immunology, University Medical Center, Utrecht
The Mechanism of Complement Activation by IgG Antibodies
Janine Schuurman, Ph.D., VP, Research, Genmab
ARGX-111, a Defucosylated Antagonistic Anti-MET Antibody that Displays Potent Anti-Tumor Activity through Enhanced ADCC
Natalie de Jonge, Ph.D., Senior Scientist, arGEN-X
Clinical Development of Tanibirumab and its Next Generation of Bispecific Antibody
Jin-San Yoo, Ph.D., CEO and President, PharmAbcine, Inc.